Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Reprod Toxicol. 2012 Jan 28;33(3):353–360. doi: 10.1016/j.reprotox.2012.01.007

Figure 2.

Figure 2

Evaluation of atresia in control and ESR1 OE antral follicles treated in vitro with vehicle, DMSO MXC, MOH or HPTE. (A) Histological sections of antral follicles were rated for atresia by comparing the presence of apoptotic bodies. Representative sections of a healthy antral follicle (top panel) and an atretic antral follicle (bottom panel) with black arrows pointing to apoptotic bodies are shown. (B) MXC (1–100 μg/ml) treated follicles; (C) MOH (0.1–10 μg/ml) treated follicles; (D) HPTE (0.1–10 μg/ml) treated follicles. Each bar represents means ± SEM. Asterisks (*) indicate significant differences from DMSO controls within genotype Bars with different letters are significantly different from each other. (n = 2–3 follicles per treatment from three separate experiments; p≤0.05).

HHS Vulnerability Disclosure